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1. Introduction
The initial discovery of mesothelioma can be traced back to 1767 when Dr. Joseph Lieutaud,
an anatomy pathologist in France, first identified a tumour in the chest wall of a young boy [1].
Mesothelioma is a rare, aggressive form of cancer that develops from transformed cells
originating in the mesothelium, which is the protective lining covering many of the body's
internal organs. Mesothelioma arises in the pleura but also occurs in the peritoneum, the tunica
vaginalis, and the pericardium [2]. Mesothelioma tends to have a local progression. While
disseminated disease has sometimes been reported in a very late stage of the disease [3– 7],
patients usually die from local progression.
2. Incidence
In Canada, there are 459 new reported cases of mesothelioma per year [8], compared to 3,000
in the United States of America. According to Connelly RR et al, the incidence of mesothelioma
in the United States is 10 cases per million people per year [9]. Men are more commonly affected
than women, with a male predominance of 90%. While there is a correlation between increasing
age and reported cases, there is no peak and the mean age at diagnosis is 60 years.
The number of cases recorded in the Quebec Tumour Database from 1982 to 2002 (for the
province of Quebec, Canada; see table 1) reveals that the incidence of pleural and peritoneal
mesothelioma was higher for men than women. The overall annual rate of increase from 1982
to 2002 in Quebec was estimated to be 3.6%, which was lower than that measured from 1982
to 1996. In comparison to the international level, only Australia and Scotland showed signifi‐
cant increases in mesothelioma among women [10].
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Type of Mesothelioma: Pleural Peritoneal
Gender: Men Women Men Women
Reported Cases: 1,210 320 98 72
Rate per 100,000 people per year: 1.98 0.41 0.15 0.09
Table 1. Incidence of Pleural and Peritoneal Mesothelioma
3. Epidemiology
3.1. Asbestos
The primary risk factor for mesothelioma is asbestos exposure. Asbestos is a generic terms for
a group of six naturally occurring silicate minerals classified as either serpentine or amphibole.
The amphibole (rod-like) group contains five types: amosite, crocidolite, anthophyllite,
tremolite, and actinolite. Serpentine (chrysotile) asbestos has a sheet or layered structure and
differs from the amphibole varieties both structurally and chemically. Chrysotile, the only
asbestos mineral in the serpentine group, is the main form of asbestos still mined. It is generally
accepted that chrysotile asbestos is less dangerous and does less damage to the lungs than the
amphiboles. Although 70% to 80% of pleural mesothelioma cases are associated with asbestos
exposure, the lifetime risk of developing pleural mesothelioma among asbestos workers is
thought to be 10% [11]. Furthermore, despite the lack of evidence between the relationship of
asbestos exposure and peritoneal mesothelioma, one study indicates that this correlation is
less significant than that between asbestos exposure and pleural mesothelioma [12].
Asbestos is still used industrially for its fire-resistance and sound-absorption properties. The
association between asbestos and mesothelioma was first documented in South African miners
[13]. Moreover, the Occupational Safety and Health Administration (OSHA) established that
0.2 fibres per cubic millilitre of air is the standard acceptable exposure rate for fibres longer
than 5 μm [14].
Construction, boiler, and shipyard workers are at increased risk. Other sources of exposure
may include a spouse or close relatives of asbestos workers. Patients from certain regions of
the world (i.e. Greece, Central Turkey, California, and Bulgaria) also have endogenous
environmental asbestos exposure as their soil contains high level of tremolite asbestos fibres
[15–19]. Furthermore, greater environmental exposure increases incidence of mesothelioma
and is also proportionate to the latency period [20–21].
In the majority of patients, the disease develops after a latency period of up to 40 years after
initial exposure [22]. Fortunately, today's strict industry standards have significantly reduced
asbestos exposure by 100 to 1,000 times compared to the past [23]. For example, Great Britain
recorded fewer annual deaths related to mesothelioma in 1968 [153] than in 2001 [1,84,8],
largely due to the latency period. The peak in mesothelioma deaths is expected to occur in 2015
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(2,450 deaths) [24]. Nevertheless, the rate of deaths in Great Britain associated with mesothe‐
lioma is expected to drop significantly after 2015, most likely because of reduced asbestos
exposure and stricter industry standards.
Although it was once thought that smoking could lead to mesothelioma, we now know that
is not the case. It does, however, increase the risk associated with asbestos exposure [25].
3.2. Carbon nanotubes
Carbon nanotubes are stronger than steel yet lighter than aluminum. As a result, they can be
found in a wide range of items such as high-performance bicycle frames, textiles (i.e. water‐
proofing fabrics), body armour, and concrete. Nevertheless, animal studies have demonstrated
that carbon nanotubes can produce mesothelioma-like changes and may therefore cause
mesothelioma [26,27]. Furthermore, it has been suggested that the mechanism involved may
be either attributed to "changes in gene expression, epigenetic changes, and receptor-mediated
or other intracellular signalling cascades" [28].
3.3. Radiation therapy
Ionizing radiation to supradiaphragmatic fields appears to be a risk factor for developing
mesothelioma. Data from patients treated with radiation therapy for Hodgkin's lymphoma
[29], non-Hodgkin's lymphoma [30], and testicular cancer [31] revealed an excess rate of
mesothelioma. Although the reported number of mesotheliomas was small, the risks were
statistically significant. This might be the result of broader radiation therapy for Hodgkin's
and non-Hodgkin's lymphoma, since mantle-field radiation had once been the standard
method of treatment. Afterwards, extended-field radiation therapy became the standard of
care. Since today’s preferred method of radiation therapy for lymphomas is involved-field
radiation, the incidence of mesotheliomas in patients with Hodgkin's or non-Hodgkin's
lymphomas should drop because the smaller radiation-therapy fields should result in fewer
secondary neoplasms. Moreover, since mediastinal radiation therapy is no longer given for
testicular seminomatous germ-cell tumours, such patients should evidence a decrease in
radiation-induced mesothelioma.
3.4. Genetic factors
Another cause for mesothelioma may be the nuclear deubiquitinase enzyme BAP1, which
plays an important role in transcriptional deregulation in the pathogenesis of mesothelio‐
ma. BAP1 deubiquitinase is known to target histones (proteins that package DNA in the
cell nucleus) and HCF1 (a transcriptional co-factor involved in the cell cycle), which also
affects  the  E2F  and  Polycomb (a  group of  genes  that  codifies  a  family  of  transcription
factors) target genes. Inactivating mutations of BAP1 were found in about one quarter of
mesothelioma tumour tissues tested [32, 33]. Common genetic changes, involving the loss
of the tumour suppressor genes p14, p16 [34],  NF-2 [35],  and P53, have been associated
with mesothelioma [2].
Mesothelioma: An Evidence-Based Review
http://dx.doi.org/10.5772/55292
179
3.5. Viral oncogenes
Simian virus 40 (SV4 0) continues to raise controversy, as it has been suggested that SV40 may
have been a contaminant in the poliomyelitis vaccine in the 1950s and 1960s. A review of
mesothelioma case studies have revealed an important presence of SV40 nucleic acid in
affected patients. SV40 is a DNA polyomavirus, which is thought to suppress tumour genes
of the retinoblastoma family by a peptide known as SV40 large T antigen [36–40].
4. Pathology
The histopathologic subtypes of mesothelioma are epithelioid (40%), mixed or biphasic (35%),
and sarcomatous or mesenchymal (25%). Needle biopsy mesothelioma can often be mistaken
for adenocarcinoma. Mesothelioma under electron microscopy reveals cells with long micro‐
villi with a needle-like shape and form. Mesothelioma is positive for calretinin, vimentin, WT1,
and cytokeratin, but negative for periodic acid-shift stain, mucicarmine stain, carcinoem‐
bryonic antigen, and Leu-M1. Adenocarcinoma under electron microscopy reveals short
microvilli [41].
5. Pathogenesis
Inhaled asbestos fibres create lung irritation that may lead to scarring, fibrosis, and plaques.
On a cellular level, injuries caused by asbestos fibres can be followed by cell repair. Repeated
cell injuries, however, may lead to DNA-strand impairment and transform into malignancy
[42]. It has also been suggested that long, thin asbestos fibres are generally more carcinogenic
than shorter, thicker ones and interfere more with mitosis, causing chromosome abnormalities
leading to cell transformation and neoplastic progression [43]. Mesothelial cells may have
increased interleukin-6 secretion, which would result in increased production of vascular
endothelial growth factor (VEGF), a signal protein produced by tumour cells that stimulates
angiogenesis [44].
6. Clinical presentation
Dyspnea and non-pleuritic chest pain are the most common presenting symptoms of meso‐
thelioma. X-rays often reveal recurrent pleural effusion or pleural thickening, which should
prompt the clinician to suspect mesothelioma [45].
Early malignant pleural mesothelioma presents as small pleural nodules. As the tumour
progresses, the nodules increase in number and coalesce to form a thickened tumour. As the
tumour replaces the pleural fluid that lies between the two pleura, the parietal and visceral
pleura fuse. This results in dyspnea and hypoxemia, which are often refractory to supplemen‐
tal oxygen when deoxygenated blood is shunted through the encased lung.
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Mesothelioma spreads by direct extension [46] and seeding throughout the pleural space,
including fissures, diaphragmatic, and pericardial surfaces; through the chest wall; and into
the mediastinum and lymph nodes. The malignancy may also extend into the abdominal
cavity. Metastasis, although uncommon, may occur in the opposite lung, brain, and other
extrathoracic sites.
7. Physical exam
The performance status should be evaluated. Visual inspection may reveal thorax nodules or
ulcers and scoliosis may be observed towards the side of the malignancy [47]. The clinician
should look at all sites of previous instrumentation for evidence of tumour seeding. Unilateral
dullness to percussion at the lung base may be observed. Decreased air entry on the involved
side may also be perceived.
8. Lab work
Tests should include a CBC, electrolytes, creatinine, and a complete metabolic panel. Serum
soluble mesothelin-related peptide and osteopontin levels could be performed, although most
Canadian centres do not currently do so.
Mesothelin is a glycoprotein usually expressed on normal mesothelial cells but is overex‐
pressed  in  epithelioid  and  mixed  mesotheliomas  [48,  49].  A  meta-analysis  showed that
sensitivity ranged from 19% to 68%, depending on the criteria chosen to establish positiv‐
ity [50]. The glycoprotein osteopontin is also overexpressed in mesothelioma, but a study
pointed to  lower diagnostic  accuracy than mesothelin in  patients  with suspected malig‐
nant mesothelioma [51].
9. Imaging
9.1. CT scan
Thoracic, abdominal, and pelvic CT scans with contrast are useful in staging the disease.
Pleural thickening is the most common finding on CT scans (92% of mesothelioma patients).
Pleural thickening is defined as either extension of more than 8 cm in the craniocaudal direction
or more than 5 cm of the chest wall when visualized in cross section, or when the pleural
thickness exceeds 3 mm [52–54].
The second most common finding is involvement of the fissure (about 85% of cases), followed
by pleural effusion (75% of patients). Other findings include contraction of a hemithorax,
contralateral shift of the mediastinum, chest-wall involvement, and rib destruction [55–58]. As
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the disease progresses, irregular pleura-based masses are common and the interlobular
fissures are often involved. CT scanning may underestimate the extent of disease.
Although CT scanning is used for tumour detection, its accuracy for detecting intrathoracic
lymph-node involvement is limited [59, 60]. Mesothelioma spreads into paraesophageal nodes,
pulmonary-ligament nodes, and diaphragmatic nodes more commonly than other lung
cancers.
9.2. MRI
Combining magnetic resonance imaging (MRI) with CT scanning may improve evaluation of
the local extent of disease. MRI helps to determine chest-wall, diaphragmatic, or apical
invasion as well as transdiaphragmatic tumour growth [57].
9.3. PET–CT scan
PET–CT scanning may be useful in detecting mediastinal lymph-node involvement or
extrathoracic diseases and to reclassify patients as inoperable [61–65].
10. Surgical staging
Although radiographic staging evaluation is warranted, accurate staging is only possible at
the time of surgery in a substantial number of patients. Pulmonary-function tests are often
performed prior to surgery. For surgical staging, mediastinoscopy or endobronchial ultra‐
sound is used in the case of suspicious nodes. An open biopsy or CT-guided core biopsy is
acceptable, but thoracenthesis or video-assisted thorascopic surgery (VATS) is preferred. If
necessary, based on the CT scan, laparoscopy can be used to rule out transdiaphragmatic
extension, and VATS to rule out contralateral disease.
11. TNM staging of mesothelioma
The TNM (Tumour, Node, Metastasis) Classification is used by both the Union for Interna‐
tional Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC). The 2010
version is the most recent.
Primary Tumour (T)
Tx: Primary tumour cannot be assessed
T0: No evidence of primary tumour
T1: Tumour limited to the ipsilateral parietal pleura, with or without mediastinal pleura and with or without
diaphragmatic pleural involvement
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T1a: No involvement of the visceral pleura
T1b: Tumour also involving the visceral pleura
T2: Tumour involves each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral
pleura) with at least one of the following:
(1) Involvement of diaphragmatic muscle
(2) Extension of tumour from visceral pleura into underlying pulmonary parenchyma
T3: Locally advanced but potentially resectable tumour. Tumour involving all of the ipsilateral pleural surfaces
(parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following:
(1) Involvement of the endothoracic fascia
(2) Extension into the mediastinal fat
(3) Solitary completely resectable focus of tumour extending into the soft tissue of the chest wall
4) Nontransmural involvement of the pericardium
T4: Locally advanced, technically unresectable tumour. Tumour involving all of the ipsilateral pleural surfaces
(parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following:
(1) Diffuse extension or multifocal masses of tumour in the chest wall, with or without associated rib
destruction
(2)Direct diaphragmatic extension of the tumour to the peritoneum
(3)Direct extension of the tumour to a mediastinal organ
(4)Direct extension of the tumour to the contralateral pleura
(5)Direct extension of the tumour into the spine
(6)Tumour extending through to the internal surface of the pericardium with or without a pericardial
effusion or tumour involving the myocardium
Regional Lymph Nodes (N)
Nx: Regional lymph nodes cannot be assessed
N0: No regional lymph-node metastases
N1: Metastases in the ipsilateral bronchopulmonary and/or hilar lymph nodes
N2: Metastases in the subcarinal or ipsilateral mediastinal lymph node (including ipsilateral internal mammary
and peridiaphragmatic nodes)
N3: Metastases in the contralateral mediastinal, internal, mammary, or hilar nodes and/or the ipsilateral or
contralateral supraclavicular or scalene lymph nodes
Distant Metastasis (M)
Mx: Distant metastasis cannot be assessed
M0: No distant metastasis
M1: Distant metastasis
Stage Groups
I T1N0M0
IA T1aN0M0
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IB T1bN0M0
II T2N0M0
III T1-2N1M0
T1-2N2M0
T3N0-2M0
IV T4 and any NMO
Any T and N3M0
Any T and any N and M1
12. Differential diagnosis
Even though most pleural tumours are malignant, the differential diagnosis also includes
benign tumours and inflammatory reactions.
Primary tumours, such as fibrosarcoma and malignant fibrous histiocytoma, can present in a
similar fashion and infiltrate like sarcomatous mesotheliomas. Metastatic diseases that can
involve the pleura and mimic epithelioid mesothelioma include breast, lung, lymphoma,
thymoma, stomach, kidney, ovarian, and prostate cancer. Finally, benign chronic organized
empyema can also mimic pleural thickening.
13. Treatments
The median survival of patients with mesothelioma is poor, ranging from 7 to 17 months [66].
The overall survival (OS) rate at 5 years is 9%. Even with new therapy interventions, the overall
patient survival rate has not been significantly improved. In some specific cases, in which
patients were specifically chosen due to their localized disease, treatment with aggressive
multimodality therapy improved their survival rates.
The first thing to consider when treating mesothelioma is whether the tumour is resectable or
not. Since the tumour spreads by direct extension, only 5% of mesotheliomas are resectable at
diagnosis. Usually T1 to T3 and N0-1 tumours are considered resectable. T4 and N2-3 tumours
are considered unresectable. Mediastinoscopy has to be performed to rule out N2-N3 lymph
nodes. In addition, patients with sarcomatoid histology have a poorer prognosis and should
not be considered for extrapleural pneumonectomy [67]. Patients must be able to tolerate
trimodal therapy, since it is important to ensure that they do not have postoperative morbid‐
ities without deriving the full benefits of surgery.
The treatment paradigms for resectable mesothelioma are:
Extrapleural pneumonectomy (EPP), then chemotherapy followed by hemithorax radiation
therapy [7, 68–71]
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Neoadjuvant chemotherapy, then EPP followed by hemithorax radiation therapy [72–73]
If the tumour is unresectable:
A combination of chemotherapy is the standard treatment. Prophylactic drain-site irradiation
should be considered.
Talc pleurodesis with a pleural catheter or pleurectomy may also be considered to palliate
symptoms of pleural effusion.
14. Surgery
Prior to surgery, it is important to have proper patient selection. Patients must have:
Performance status of 0–1
PaO2 of more than 65 mm Hg
PaCO2 of less than 45 mm Hg
A predicted post op FEV1 of more than 1 L
An ejection fraction of more than 40%
A mean pulmonary arterial pressure of less than 30 mm Hg
An epithelioid histology
14.1. Extrapleural Pneumonectomy (EPP)
EPP involves the removal of parietal pleura, lung, pericardium, and ipsilateral diaphragm.
Mediastinal node dissection is usually performed. Finally, a graft is inserted to prevent
herniation of abdominal contents through the diaphragmatic defect. Although no survival
benefit was observed from randomized trials, observational studies indicated that EPP is the
only intervention that has been demonstrated to result in long-term, disease-free survival in
highly selected patients with favourable prognostic indication [7]. In a review of 83 patients
who underwent EPP, the observed 5-year survival rate was 15% [74].
The  benefits  of  EPP  is  that  it  allows  complete  resection  or  at  least  a  cytoreduction,
permitting higher radiation doses to be delivered safely to the ipsilateral hemithorax. This
procedure has the disadvantage of being technically complex and associated with signifi‐
cant perioperative morbidity and mortality. Complications include atrial fibrillation (44.2%),
prolonged  intubation  (7.9%),  vocal-cord  paralysis  (6.7%),  deep-vein  thrombosis  (6.4%),
technical complications (patch dehiscence, haemorrhage, or both; 6.1%), tamponade (3.6%),
acute  respiratory-distress  syndrome  (3.6%),  cardiac  arrest  (3%),  constrictive  physiology
(2.7%),  aspiration  (2.7%),  renal  failure  (2.7%),  empyema  (2.4%),  tracheostomy  1.8%,
myocardial infarction (1.5%), pulmonary embolus (1.5%), and bronchopleural fistula (0.6%)
[75]. In extensive experience, the early postoperative mortality rate approaches 7% [76] but
can be as high as 30%. The mean survival (MS) rate after surgery is 4 to 20 months.
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14.2. Pleurectomy/Decortication (P/D)
In case of more advanced disease, mixed histology, and medically high-risk operable patients,
pleurectomy/decortication is preferred over EPP. Pleurectomy/decortication is performed in
two phases. Phase 1 is pleurectomy and involves removing the pleural lining. Phase 2 is
decortication, which is the removal of any tumour growing inside the lining. The procedure's
perioperative mortality is 4% [76].
Retrospective studies have indicated that parietal pleurectomy and decortication may be as
efficient as extrapleural pneumonectomy [76]. When comparing EPP to PD, it was observed
that PD patients had a greater local recurrence of disease, while EPP patients experienced
higher mortality and surgical morbidity.
15. Radiotherapy (RT)
15.1. Adjuvant radiation therapy after EPP
Radiation therapy is a local treatment that uses ionizing radiation to destroy tumour cells. As
mentioned above, aggressive surgery alone does not improve survival. Observational data do
not provide evidence that adjuvant RT following pleurectomy offers a survival benefit [77].
That notwithstanding, the MSKCC phase-II trial with hemithorax radiotherapy to 54 Gy
following EPP showed improved mean survival rates at 34 months for stage I-II disease and
at 10 months with later-stage disease compared to historical controls [78]. In addition to a small
survival benefit demonstrated in the MSKCC study, the rationale for using radiation therapy
is local control. The disease is of a diffuse nature and manipulating the exposed tumour during
EPP puts the entire ipsilateral chest wall, diaphragm insertion, pericardium, mediastinum, and
bronchial stump at a very high risk of local recurrence, as high as 80% of patients, as reported
in [78]. The evaluation of high-dose radiation therapy showed that the use of adjuvant
radiation decreased the risk of local recurrence to 13% [78].
Mesothelioma is considered a tumour sensitive to external-beam radiation therapy. The
recommended postoperative doses are 50 Gy for negative surgical margins, 54 to 60 Gy for
close or positive margins, and 60 Gy for gross tumours [79–83]. The radiation dose has to be
limited, however, due to the treatment required to the entire hemithorax and the sensitivity
of critical organs such as the heart, lungs, oesophagus, liver, kidneys, and spinal cord to
radiation [68].
Treatment volumes include ipsilateral mediastinum even for node-negative tumours. The
superior border should include the thoracic inlet. The medial border should include the
trachea, subcarinal lymph nodes, and the vertebral body. The inferior border is the insertion
of the diaphragm, ranging from L1 to L4. Radiation oncologists should be careful to include
the anteromedial pleural reflection of the sternopericardial recess, the medial and inferior
extent of the crus of the diaphragm, and the inferior insertion of the diaphragm in the treatment
volume. Nowadays, radiation therapy is delivered using three-dimensional conformal
radiation therapy (3DCRT) or intensity-modulated radiation therapy (IMRT) [70, 71, 84, 85].
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IMRT can be delivered according to the method published by the MDACC experiment using
13 to 27 fields with 8 to 11 gantry angles with 100 segments/fields. The target volume was the
entire hemithorax, all surgical clips, all sites of instrumentation, and the ipsilateral mediasti‐
num with an initial dose to 45-50 Gy, with a boost to 60 Gy for a close/positive margin. The
two-year survival rate was 62% and the three-year disease-free survival (DFS) rate was 45%
for negative lymph nodes and epithelioid histology. Five patients with stage-I disease had a
three-year DFS of 100%. IMRT has the potential to decrease pulmonary toxicity if correct
treatment algorithms are applied.
In order to decrease the side effects of radiation therapy, several dose-volume restrictions are
applied. The V20 (the volume receiving 20 Gy or more) of the lung must not exceed 7%, since
Rice DC et al. [86] showed a relative risk of 42% for fatal pneumonitis. The oesophagus V55
should be less than 30%; the liver V30 should be less than 30%. The kidneys V15 should be less
than 20%; the heart V40 less than 50%; the spinal cord V45 less than 10%; no volume should
be more than 50 Gy.
15.2. Radiation therapy to the biopsy site
A  debate  in  radiation  oncology  for  mesothelioma  remains  whether  to  offer  radiation
therapy to inoperable patients following an invasive procedure or following a biopsy in
order  to  avoid  needle-tract  seeding from the  tumour.  The  incidence  of  tumour  seeding
along the biopsy tract may range from 0% to 43% and may lead to the formation of painful
subcutaneous  lesions  [87].  Three  randomized  trials  [88–90]  evaluated  RT  following
thoracoscopy or thoracotomy to prevent tumour seeding. The radiation-therapy regimen
was  generally  3  fractions  of  7  Gy  (total  of  21  Gy).  O’Rouke  et  al.  showed,  in  their
randomized trial  with 61 patients,  that  prophylactic  radiation therapy to drain sites  did
not  statistically  reduce the  rate  of  seeding.  Boutin’s  study (40  patients)  revealed a  clear
benefit of radiation at the biopsy site with reduction of biopsy-tract metastasis from 40%
to 0% (p < 0.00 1). At the Hôtel-Dieu de Québec Hospital, however, Marie-Anne Froment
et al.  [91] reported a benefit  of radiation therapy to avoid needle-tract seeding from the
tumour.  At  6  months,  local  progression-free  survival  for  the intervention sites  was 91%
with  prophylactic  radiation  therapy  and  74%  without  irradiation  (p  =  0.00  2).  During
follow-up, 6 patients (13%) in the treated group had tumour invasion of the subcutane‐
ous  tissue  compared  to  40  patients  (33%)  in  the  group  without  radiation  (p  =  0.00  8).
Because recurrence is morbid and this treatment is easily feasible, Hôtel-Dieu de Québec
Hospital generally offers radiation therapy to such patients.
15.3. Side effects of radiation therapy after EPP
The side effects of radiation therapy can be classified according to time of occurrence: acute,
intermediate, or late. Acute effects, if they appear, are expected to start during treatment
and  be  resolved  within  3  months  following  treatment.  Potential  acute  side  effects  are
fatigue,  skin  reactions,  nausea,  vomiting,  dysphagia,  odynophagia,  and cough.  Potential
intermediate  side  effects  include  pneumonitis  and Hermitte’s  syndrome.  If  intermediate
side effects occur, they usually do so 3 months after treatment and resolve within 6 months.
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Finally, potential late effects would occur 6 months following treatment and could include
pulmonary  fibrosis,  pericarditis,  restrictive  cardiomyopathy,  myocardial  infarction,
congestive heart failure, and radiation myelopathy.
16. Chemotherapy
Adjuvant or Neoadjuvant Chemotherapy
Anthracyclines have historically been the most commonly used pharmacologic agents, with
reported response rates of 19% [92]. Recent trials using platinum in combination with folate
analogues have improved cytotoxic activity against mesothelioma. The preferred treatment
during these recent trials was a combination of chemotherapy incorporated with a trimodal
regimen, as adjuvant or neoadjuvant chemotherapy options are either pemetrexed/cisplatin
or gemcitabine/cisplatin.
16.1. Adjuvant chemotherapy
Patients treated with EPP, followed by radiation therapy and adjuvant chemotherapy, had a
median survival rates of 36 % and 14% at two to five years, respectively. Historically, the
chemotherapy used was doxorubicin, cyclophosphamide, and cisplatin for four to six cycles
[93]. A Harvard retrospective [93] review of 183 patients treated with a trimodality approach
using adjuvant chemotherapy of Cytoxan/Adriamycin/cisplatin (CAP) or carboplatin/Taxol
with concurrent radiation therapy followed by adjuvant chemotherapy had an overall mean
survival rate of 19 months and a 5-year overall survival (OS) rate of 15%.
16.2. Neoadjuvant chemotherapy
The rationale for using neoadjuvant chemotherapy prior to surgery is that it may increase
tolerance and improve response to surgery. A multicenter phase-II trial [72] evaluated the role
of neoadjuvant chemotherapy prior to EPP and RT. The chemotherapy consisted of four cycles
of pemetrexed plus cisplatin. The median survival rate of the patients who completed the
therapy was 29 months; the two-year survival rate was 61%. De Perrot et al. [73] reported a
median survival rate of 59 months in a subgroup of patients who had completed trimodal
therapy with neoadjuvant chemotherapy, EPP, and then RT. The median survival rate was less
than 14 months for the patients who did not complete the treatment regimen.
Chemotherapy as a definitive treatment
16.3. Combination chemotherapy
Combination-chemotherapy regimens using pemetrexed and platinum-based agents have
yielded superior outcomes than single agents. Volgezang NJ et al. [94] showed that, for
unresectable tumours, cisplatin/pemetrexed improved the response rate of 17% vs. 40% and
the MS rate from 9 to 12 months compared to cisplatin alone. In 2004, pemetrexed became the
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first agent to receive Food and Drug Administration (FDA) approval for use in combination
with cisplatin. The combination of pemetrexed and carboplatin were studied in two phase-II
studies, the response rates and mean survival rates were 18.6% and 12.7 months in the Ceresoli
study [95] and 25% and 14 months in the Castagneto study [96].
Several trials [97, 98] have evaluated the addition of gemcitabine, a cytidine analogue. Only
38% of patients received the four cycles as prescribed and the response rate was 26% among
those who completed the treatment [98]. It should be noted that the study only included early-
stage mesothelioma. Vinca alkaloid-containing regimen was compared to MVP (mitomycin,
vinblastine, and cisplatin) in terms of symptom control. The median survival benefit was an
additional 2 months [99].
16.4. Single-agent chemotherapy
Pemetrexed as a single agent has been studied. In one phase-II trial [100], the study design was
revised to incorporate folic acid and cynocobalamin in addition to dexamethasone. The median
progression-free survival was 16.3 months in the pemetrexed/vitamin-supplemented group
versus 9.5 months for the pemetrexed group. Other single agents such as gemcitabine,
anthracyclines, and taxanes have been tested but resulted in low response rates, such as 10%
16.5. Chemotherapy side effects
Cisplatin and carboplatin are platinum analogues. The potential side effects of platinum agents
include dose-limiting myelosuppression, nausea, vomiting, renal impairment, hearing
impairment, and peripheral neuropathy. Pemetrexed is an antifolate compound. Potential side
effects include myelosuppression, nausea, skin rash, alopecia, diarrhoea, and fatigue.
17. Molecular target therapy
Recent anticancer agents focus on molecular targets such as surface receptors and cell-
signalling proteins. Although it has been shown that mesothelial cells express the vascular
endothelial growth factor (VEGF) receptor, a recent study [101] failed to demonstrate survival
improvement with bevacizumab. Erlotinib, a tyrosine-kinase inhibitor of the epidermal
growth-factor receptor (EGFR), was tested in a phase-II trial. EGFR is expressed primarily in
the epithelial subtype of mesothelioma. Of the 63 patients who were enrolled, only 29 were
assessed for outcomes; no objective responses were reported [102].
18. Prognosis and overall survival
The European Organisation for Research and Treatment of Cancer (EORTC) reviewed data for
204 adults who were enrolled in five consecutive phase-II trials over nine years. The EORTC
poor prognostic factors [103] for mesothelioma are:
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• White-blood-cell count greater than 8.3 X 109/ dL
• Performance status (PS) 1-2
• Sarcomatous histology
• Male gender
For low risk: 1-year OS rate is 40%; 2-year OS rate is 14%. For high risk: 1-year OS rate is 12%
and 2-years OS rate is 0%. The MS rates are 4 and 12 months, respectively.
19. Palliative treatment
Surgical procedures, radiation therapy, and chemotherapy can be used to palliate symptoms.
19.1. Surgery
Large pleural effusions can cause persistent dyspnea and pain. Complete drainage of the
pleural effusion by tube thoracostomy or video thoracoscopy followed by the introduction of
an irritative agent to obliterate the pleural space can provide palliation. There is an ongoing
randomized trial in the United Kingdom comparing the palliative benefits of VATS pleurec‐
tomy to talc pleurodesis.
19.2. Radiation therapy
In the case of palliative treatments, radiation therapy can be used for pain relief. Either 30 Gy
in 10 fractions or 20 Gy in 5 fractions can be delivered. Furthermore, palliative radiation
therapy with daily dose of 4 Gy appears to be more effective than fractionations of less than 4
Gy for a total dose of 20 to 40 Gy to relieve pain associated with skin nodules in the CW.
Radiation therapy can alleviate symptoms in 50% of patients [104].
19.3. Chemotherapy
For unresectable tumours, palliative chemotherapy with cisplatin/pemetrexed or cisplatin/
gemcitabine can be used. There are no standard second line of chemotherapy. Therefore, a
combination or single agent such as gemcitabine, vinorelbine, paclitaxel, or docetaxel may be
considered.
20. Conclusion
The highest risk factor for mesothelioma is exposure to asbestos. Treatment for mesothelioma
involves a trimodal approach for early-stage disease, which includes surgery, radiation, and
systemic chemotherapy. In the case of locally advanced disease, nonsurgical candidates, or
metastatic disease, surgery, chemotherapy, or radiation therapy can be used. Mesothelioma
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has a poor prognosis, but recent studies of pemetrexed and platinum-analogue combination
therapies have demonstrated improved response rates over other treatments. Although
conducting research on mesothelioma is extremely difficult, since it is an uncommon disease,
further study is required to improve patient outcomes.
Nomenclature
AP Anterior-posterior field
BAP1 A gene that encodes a nuclear localizing protein with a ubiquitin carboxy-terminal
hydrolase domain that gives BAP1 its deubiquitinase activity.
CAP Cytoxan/Adriamycin/cisplatin
CBC Complete blood count
CW Chest wall
DFS Disease-free survival
E2F Group of genes that codifies a family of transcription factors
EGFR Epidermal growth-factor receptor
EORTC European Organisation for Research and Treatment of Cancer
EPP Extrapleural pneumonectomy
FDA Food and Drug Administration
Gy Gray
HCF1 A transcriptional cofactor involved in the cell cycle
MS Mean survival
MVP Mitomycin, vinblastine, and cisplatin
NF-2 Neurofibromatosis type-2 gene
OS Overall survival
P14 Tumour suppressor gene
P16 Tumour suppressor gene
P53 Tumour suppressor gene
PA Posterior-anterior field
P/D: Pleurectomy/decortication
PS Performance status
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RT Radiation therapy
VATS Video-assisted thoracoscopic surgery
VEGF Vascular endothelial growth factor
WT1 Wilm’s tumour gene
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